|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||117.40 - 119.85|
|52 Week Range||70.80 - 122.19|
|Beta (3Y Monthly)||0.51|
|PE Ratio (TTM)||523.20|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||106.88|
Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $1.72 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Improving payer accessIn the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members. According to
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s pump demandIn the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%. The demand rose
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s revenue trajectoryIn its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson
Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California.
No-Cost Personal Diabetes Manager, No Four Year Lock-in Period, and New User Interface Allow for Smooth Transition from Multiple Daily Injections to Pod Therapy
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This week's podcast discussion is all about vertical violations, which can be used to spot a potentially prolonged stock market correction.
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.
In the first quarter, the tubeless insulin pump specialist's revenue growth accelerated and it raised its full-year 2019 guidance.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.